Abbisko Cayman LimitedHKEX: 2256

2026 Interim report

· Issued by Abbisko Cayman Limited via HKEXnews

Filed with HKEX · Stock code 2256 · · 97 pages · English

Summary by 6ix AI

The report indicates a commercial launch of their lead asset, pimicotinib, in China, alongside advancements in various clinical programs. Financially, the company reported a notable decrease in revenue compared to the previous year, primarily due to changes in licensing income. Despite the revenue drop, Abbisko maintains a strong financial position with substantial cash reserves to support ongoing innovation.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Abbisko Cayman Limited on 6ix

Earlier from Abbisko Cayman

Later from Abbisko Cayman

All Abbisko Cayman news releases